Inhibition of autoimmune diabetes by TLR2 tolerance

Journal of Immunology

Volumn 187, Issue 10, 2011, Pages 5211-5220

  Kim, Do Hoon ^a   Lee, June Chul ^a   Kim, Sunshin ^b   Oh, Seung Hoon ^a   Lee, Moon Kyu ^a   Kim, Kwang Won ^a   Lee, Myung Shik ^a,c  

^a Samsung Medical Center   (South Korea)

^b National Cancer Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12P40; PAM3CSK4; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; AUTOIMMUNE DIABETES MELLITUS; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DIABETES MELLITUS; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UPREGULATION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; IMMUNE TOLERANCE; INSULIN-SECRETING CELLS; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; TOLL-LIKE RECEPTOR 2;

EID: 81455135857     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001388     Document Type: Article

References (53)

1. Trudeau, J. D., J. P. Dutz, E. Arany, D. J. Hill, W. E. Fieldus, and D. T. Finegood. 2000. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49: 1-7. (Pubitemid 30022916)
2. Turley, S., L. Poirot, M. Hattori, C. Benoist, and D. Mathis. 2003. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J. Exp. Med. 198: 1527-1537. (Pubitemid 37467167)
3. Kim, H. S., M. S. Han, K. W. Chung, S. Kim, E. Kim, M. J. Kim, E. Jang, H. A. Lee, J. Youn, S. Akira, and M.-S. Lee. 2007. Toll-like receptor 2 senses link beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333. (Pubitemid 47284922)
4. Cavaillon, J. M., C. Adrie, C. Fitting, and M. Adib-Conquy. 2003. Endotoxin tolerance: is there a clinical relevance? J. Endotoxin Res. 9: 101-107. (Pubitemid 36603684)
5. Siedlar, M., M. Frankenberger, E. Benkhart, T. Espevik, M. Quirling, K. Brand, M. Zembala, and L. Ziegler-Heitbrock. 2004. Tolerance induced by the lipopeptide Pam3Cys is due to ablation of IL-1R-associated kinase-1. J. Immunol. 173: 2736-2745. (Pubitemid 39063135)
6. Suk, K., S. Kim, Y.-H. Kim, K.-A. Kim, I. Chang, H. Yagita, M. Shong, and M.-S. Lee. 2001. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 in pancreatic beta cell death. J. Immunol. 166: 4481-4489. (Pubitemid 32233732)
7. Kim, H. S., and M.-S. Lee. 2005. Essential role of STAT1 in caspase-independent cell death of activated macrophages through the p38 mitogen-activated protein kinase/STAT1/reactive oxygen species pathway. Mol. Cell. Biol. 25: 6821-6833. (Pubitemid 41023252)
8. Judkowski, V., C. Pinilla, K. Schroder, L. Tucker, N. Sarvetnick, and D. B. Wilson. 2001. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166: 908-917. (Pubitemid 32060245)
9. Robertson, J. M., P. E. Jensen, and B. D. Evavold. 2000. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 164: 4706-4712. (Pubitemid 30238071)
10. Kim, S., K.-A. Kim, D.-Y. Hwang, T. H. Lee, N. Kayagaki, H. Yagita, and M.-S. Lee. 2000. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J. Immunol. 164: 2931-2936. (Pubitemid 30148950)
11. Jung, H. S., K. W. Chung, J. Won Kim, J. Kim, M. Komatsu, K. Tanaka, Y. H. Nguyen, T. M. Kang, K. H. Yoon, J. W. Kim, et al. 2008. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab. 8: 318-324.
12. Qin, H.-Y., M. W. Sadelain, C. Hitchon, J. Lauzon, and B. Singh. 1993. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J. Immunol. 150: 2072-2080. (Pubitemid 23129686)
13. Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082. (Pubitemid 47410281)
14. Adib-Conquy, M., and J. M. Cavaillon. 2002. Gamma interferon and granulocyte/ monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J. Biol. Chem. 277: 27927-27934. (Pubitemid 34966740)
15. Hatao, F., M. Muroi, N. Hiki, T. Ogawa, Y. Mimura, M. Kaminishi, and K.-i. Tanamoto. 2004. Prolonged Toll-like receptor stimulation leads to downregulation of IRAK-4 protein. J. Leukoc. Biol. 76: 904-908. (Pubitemid 39313728)
16. Kobayashi, K., L. D. Hernandez, J. E. Galán, C. A. Janeway, Jr., R. Medzhitov, and R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202. (Pubitemid 34876547)
17. van 't Veer, C., P. S. van den Pangaart, M. A. D. van Zoelen, M. de Kruif, R. S. Birjmohun, E. S. Stroes, A. F. de Vos, and T. van der Poll. 2007. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J. Immunol. 179: 7110-7120.
18. Yanagawa, Y., and K. Onoé. 2007. Enhanced IL-10 production by TLR4- and TLR2-primed dendritic cells upon TLR restimulation. J. Immunol. 178: 6173-6180. (Pubitemid 46717399)
19. Imanishi, T., H. Hara, S. Suzuki, N. Suzuki, S. Akira, and T. Saito. 2007. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 178: 6715-6719. (Pubitemid 46847393)
20. Sutmuller, R. P., M. H. den Brok, M. Kramer, E. J. Bennink, L. W. Toonen, B. J. Kullberg, L. A. Joosten, S. Akira, M. G. Netea, and G. J. Adema. 2006. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116: 485-494. (Pubitemid 43228366)
21. Jaeschke, A., M. Rincón, B. Doran, J. Reilly, D. Neuberg, D. L. Greiner, L. D. Shultz, A. A. Rossini, R. A. Flavell, and R. J. Davis. 2005. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes. Proc. Natl. Acad. Sci. USA 102: 6931-6935. (Pubitemid 40675419)
22. Szanya, V., J. Ermann, C. Taylor, C. Holness, and C. G. Fathman. 2002. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169: 2461-2465. (Pubitemid 34920990)
23. Tang, Q., J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, and J. A. Bluestone. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
24. Nakayama, K., S. Okugawa, S. Yanagimoto, T. Kitazawa, K. Tsukada, M. Kawada, S. Kimura, K. Hirai, Y. Takagaki, and Y. Ota. 2004. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J. Biol. Chem. 279: 6629-6634. (Pubitemid 38248800)
25. Li, C. H., J. H. Wang, and H. P. Redmond. 2006. Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. J. Leukoc. Biol. 79: 867-875.
26. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379. (Pubitemid 38500085)
27. Foster, S. L., D. C. Hargreaves, and R. Medzhitov. 2007. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447: 972-978. (Pubitemid 46975746)
28. Chau, T. A., M. L. McCully, W. Brintnell, G. An, K. J. Kasper, E. D. Vinés, P. Kubes, S. M. Haeryfar, J. K. McCormick, E. Cairns, et al. 2009. Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat. Med. 15: 641-648.
29. Dobrovolskaia, M. A., A. E. Medvedev, K. E. Thomas, N. Cuesta, V. Toshchakov, T. Ren, M. J. Cody, S. M. Michalek, N. R. Rice, and S. N. Vogle. 2003. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J. Immunol. 170: 508-519. (Pubitemid 36026178)
30. Serreze, D. V., K. Hamaguchi, and E. H. Leiter. 1989. Immunostimulation circumvents diabetes in NOD/Lt mice. J. Autoimmun. 2: 759-776.
31. Quintana, F. J., A. Rotem, P. Carmi, and I. R. Cohen. 2000. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 165: 6148-6155.
32. Balasa, B., K. Van Gunst, and N. Sarvetnick. 2000. The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of autoimmune diabetes. Clin. Immunol. 95: 93-98. (Pubitemid 30317818)
33. Lee, B. J., S. K. Kim, M. K. Kim, E. S. Park, H. C. Cho, M. S. Shim, M. J. Kim, Y. G. Shin, and C. H. Chung. 2005. Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice. Yonsei Med. J. 46: 341-346. (Pubitemid 40959873)
34. Karumuthil-Melethil, S., N. Perez, R. Li, and C. Vasu. 2008. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J. Immunol. 181: 8323-8334.
35. Burton, O. T., P. Zaccone, J. M. Phillips, H. De La Peña, Z. Fehérvári, M. Azuma, S. Gibbs, B. Stockinger, and A. Cooke. 2010. Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice. J. Immunol. 185: 2754-2762.
36. Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill. 2003. Collaborative induction of inflammatory responses by dectin-1 and Tolllike receptor 2. J. Exp. Med. 197: 1107-1117. (Pubitemid 36570066)
37. Lamkanfi, M., R. K. Malireddi, and T. D. Kanneganti. 2009. Fungal zymosan and mannan activate the cryopyrin inflammasome. J. Biol. Chem. 284: 20574-20581.
38. Mizuno, M., Y. Ito, N. Hepburn, T. Mizuno, Y. Noda, Y. Yuzawa, C. L. Harris, B. P. Morgan, and S. Matsuo. 2009. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. J. Immunol. 183: 1403-1412.
39. Yoshitomi, H., N. Sakaguchi, K. Kobayashi, G. D. Brown, T. Tagami, T. Sakihama, K. Hirota, S. Tanaka, T. Nomura, I. Miki, et al. 2005. A role for fungal beta-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201: 949-960. (Pubitemid 40524464)
40. van Duin, D., R. Medzhitov, and A. C. Shaw. 2006. Triggering TLR signaling in vaccination. Trends Immunol. 27: 49-55. (Pubitemid 43083564)
41. Bulut, Y., E. Faure, L. Thomas, O. Equils, and M. Arditi. 2001. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol. 167: 987-994. (Pubitemid 32660856)
42. Habal, N., R. K. Gupta, A. J. Bilchik, R. Yee, Z. Leopoldo, W. Ye, R. M. Elashoff, and D. L. Morton. 2001. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. 8: 389-401. (Pubitemid 32524761)
43. Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen, J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, and D. S. Krause; Lyme Disease Vaccine Study Group. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339: 209-215. (Pubitemid 28350162)
44. Stockfleth, E., U. Trefzer, C. Garcia-Bartels, T. Wegner, T. Schmook, and W. Sterry. 2003. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. 149(Suppl. 66): 53-56. (Pubitemid 38064520)
45. Vermorken, J. B., A. M. Claessen, H. van Tinteren, H. E. Gall, R. Ezinga, S. Meijer, R. J. Scheper, C. J. Meijer, E. Bloemena, J. H. Ransom, et al. 1999. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353: 345-350. (Pubitemid 29088160)
46. Höhlich, B. J., K. H. Wiesmüller, B. Haas, W. Gerner, R. Correa, H. R. Hehnen, T. Schlapp, E. Pfaff, and A. Saalmüller. 2003. Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes. J. Gen. Virol. 84: 3315-3324. (Pubitemid 37540759)
47. Kudryashov, V., P. W. Glunz, L. J. Williams, S. Hintermann, S. J. Danishefsky, and K. O. Lloyd. 2001. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc. Natl. Acad. Sci. USA 98: 3264-3269. (Pubitemid 32220834)
48. Zhu, X., T. V. Ramos, H. Gras-Masse, B. E. Kaplan, and L. BenMohamed. 2004. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 34: 3102-3114. (Pubitemid 39549389)
49. Wiedemann, F., R. Link, K. Pumpe, U. Jacobshagen, H. E. Schaefer, K. H. Wiesmüller, R. P. Hummel, G. Jung, W. Bessler, and T. Böltz. 1991. Histopathological studies on the local reactions induced by complete Freund's adjuvant (CFA), bacterial lipopolysaccharide (LPS), and synthetic lipopeptide (P3C) conjugates. J. Pathol. 164: 265-271.
50. Seth, A., Y. Yasutomi, H. Jacoby, J. C. Callery, S. M. Kaminsky, W. C. Koff, D. F. Nixon, and N. L. Letvin. 2000. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res. Hum. Retroviruses 16: 337-343. (Pubitemid 30132088)
51. Heikenwalder, M., M. Polymenidou, T. Junt, C. Sigurdson, H. Wagner, S. Akira, R. Zinkernagel, and A. Aguzzi. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10: 187-192. (Pubitemid 38524890)
52. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, et al. 2004. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113: 1473-1481. (Pubitemid 39071703)
53. Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559. (Pubitemid 46830615)